Skip to main content
Journal cover image

Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.

Publication ,  Journal Article
Ueno, T; Ko, SH; Grubbs, E; Pruitt, SK; Friedman, HS; Tyler, DS
Published in: Am J Surg
November 2004

BACKGROUND: Regional infusion therapy with melphalan (LPAM) is an accepted treatment for advanced extremity melanoma. However, much room exists for improving the therapeutic index of this type of therapy. METHODS: Isolated limb infusion (ILI) with temozolomide (TMZ), a novel methylating agent, was performed using a nude rat bearing human melanoma xenograft. Additional rats were treated systemically with TMZ, or regionally with LPAM or 10% dimethyl sulfoxide (DMSO; control) using ILI. RESULTS: Rats that received systemic TMZ showed a poor tumor response and no tumor regression. In contrast, intra-arterial TMZ demonstrated a prolongation of tumor growth delay in a dose-responsive manner. In comparison with LPAM of equitoxic dose, TMZ provided both longer tumor growth delay and a greater number of tumor regressions. CONCLUSIONS: These data suggest that ILI with TMZ is an effective treatment for advanced extremity melanoma and may be better than LPAM in this setting.

Duke Scholars

Published In

Am J Surg

DOI

ISSN

0002-9610

Publication Date

November 2004

Volume

188

Issue

5

Start / End Page

532 / 537

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Transplantation, Heterologous
  • Temozolomide
  • Survival Rate
  • Surgery
  • Skin Neoplasms
  • Severity of Illness Index
  • Sensitivity and Specificity
  • Reference Values
  • Rats, Nude
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ueno, T., Ko, S. H., Grubbs, E., Pruitt, S. K., Friedman, H. S., & Tyler, D. S. (2004). Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am J Surg, 188(5), 532–537. https://doi.org/10.1016/j.amjsurg.2004.07.014
Ueno, Tomio, Sae Hee Ko, Elizabeth Grubbs, Scott K. Pruitt, Henry S. Friedman, and Douglas S. Tyler. “Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.Am J Surg 188, no. 5 (November 2004): 532–37. https://doi.org/10.1016/j.amjsurg.2004.07.014.
Ueno T, Ko SH, Grubbs E, Pruitt SK, Friedman HS, Tyler DS. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am J Surg. 2004 Nov;188(5):532–7.
Ueno, Tomio, et al. “Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.Am J Surg, vol. 188, no. 5, Nov. 2004, pp. 532–37. Pubmed, doi:10.1016/j.amjsurg.2004.07.014.
Ueno T, Ko SH, Grubbs E, Pruitt SK, Friedman HS, Tyler DS. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am J Surg. 2004 Nov;188(5):532–537.
Journal cover image

Published In

Am J Surg

DOI

ISSN

0002-9610

Publication Date

November 2004

Volume

188

Issue

5

Start / End Page

532 / 537

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Transplantation, Heterologous
  • Temozolomide
  • Survival Rate
  • Surgery
  • Skin Neoplasms
  • Severity of Illness Index
  • Sensitivity and Specificity
  • Reference Values
  • Rats, Nude